J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.